» Articles » PMID: 19936230

Pseudomonas Aeruginosa Population Structure Revisited

Overview
Journal PLoS One
Date 2009 Nov 26
PMID 19936230
Citations 120
Authors
Affiliations
Soon will be listed here.
Abstract

At present there are strong indications that Pseudomonas aeruginosa exhibits an epidemic population structure; clinical isolates are indistinguishable from environmental isolates, and they do not exhibit a specific (disease) habitat selection. However, some important issues, such as the worldwide emergence of highly transmissible P. aeruginosa clones among cystic fibrosis (CF) patients and the spread and persistence of multidrug resistant (MDR) strains in hospital wards with high antibiotic pressure, remain contentious. To further investigate the population structure of P. aeruginosa, eight parameters were analyzed and combined for 328 unrelated isolates, collected over the last 125 years from 69 localities in 30 countries on five continents, from diverse clinical (human and animal) and environmental habitats. The analysed parameters were: i) O serotype, ii) Fluorescent Amplified-Fragment Length Polymorphism (FALFP) pattern, nucleotide sequences of outer membrane protein genes, iii) oprI, iv) oprL, v) oprD, vi) pyoverdine receptor gene profile (fpvA type and fpvB prevalence), and prevalence of vii) exoenzyme genes exoS and exoU and viii) group I pilin glycosyltransferase gene tfpO. These traits were combined and analysed using biological data analysis software and visualized in the form of a minimum spanning tree (MST). We revealed a network of relationships between all analyzed parameters and non-congruence between experiments. At the same time we observed several conserved clones, characterized by an almost identical data set. These observations confirm the nonclonal epidemic population structure of P. aeruginosa, a superficially clonal structure with frequent recombinations, in which occasionally highly successful epidemic clones arise. One of these clones is the renown and widespread MDR serotype O12 clone. On the other hand, we found no evidence for a widespread CF transmissible clone. All but one of the 43 analysed CF strains belonged to a ubiquitous P. aeruginosa "core lineage" and typically exhibited the exoS(+)/exoU(-) genotype and group B oprL and oprD alleles. This is to our knowledge the first report of an MST analysis conducted on a polyphasic data set.

Citing Articles

Genetic Diversity in Antimicrobial Resistance Determinants Among Pathogenic Pseudomonas aeruginosa in India.

Rathod M, Shukla S, Sanapala P, Rajni E, Maheshwari G, Gajjar D Curr Microbiol. 2025; 82(5):189.

PMID: 40080202 DOI: 10.1007/s00284-025-04174-5.


Vaccine Development: Lessons, Challenges, and Future Innovations.

Santamarina-Fernandez R, Fuentes-Valverde V, Silva-Rodriguez A, Garcia P, Moscoso M, Bou G Int J Mol Sci. 2025; 26(5).

PMID: 40076637 PMC: 11900337. DOI: 10.3390/ijms26052012.


Molecular Typing of Isolates Collected in Abidjan Hospitals (Côte d'Ivoire) Using the Multiple-Locus Variable Number of Tandem Repeats Method.

Essoh C, Hauck Y, Ouassa T, Toure D, Djatchi R, Loukou G Diagnostics (Basel). 2024; 14(20).

PMID: 39451606 PMC: 11506784. DOI: 10.3390/diagnostics14202284.


Common regulatory mutation increases single-cell survival to antibiotic exposures in .

Ritz D, Deng Y, Schultz D bioRxiv. 2024; .

PMID: 39345531 PMC: 11430049. DOI: 10.1101/2024.09.20.614194.


Antibiofilm activity of species from the cystic fibrosis lung microbiota against .

Grassi L, Asfahl K, Van den Bossche S, Maenhout I, Sass A, Vande Weygaerde Y Biofilm. 2024; 7:100206.

PMID: 38975276 PMC: 11225020. DOI: 10.1016/j.bioflm.2024.100206.


References
1.
Chambers D, Scott F, Bangur R, Davies R, Lim A, Walters S . Factors associated with infection by Pseudomonas aeruginosa in adult cystic fibrosis. Eur Respir J. 2005; 26(4):651-6. DOI: 10.1183/09031936.05.00126704. View

2.
Ruimy R, Genauzeau E, Barnabe C, Beaulieu A, Tibayrenc M, Andremont A . Genetic diversity of Pseudomonas aeruginosa strains isolated from ventilated patients with nosocomial pneumonia, cancer patients with bacteremia, and environmental water. Infect Immun. 2000; 69(1):584-8. PMC: 97924. DOI: 10.1128/IAI.69.1.584-588.2001. View

3.
Goldberg J . Pseudomonas: global bacteria. Trends Microbiol. 2001; 8(2):55-7. DOI: 10.1016/s0966-842x(99)01671-6. View

4.
Tassios P, Gennimata V, Maniatis A, Fock C, Legakis N . Emergence of multidrug resistance in ubiquitous and dominant Pseudomonas aeruginosa serogroup O:11. The Greek Pseudomonas Aeruginosa Study Group. J Clin Microbiol. 1998; 36(4):897-901. PMC: 104657. DOI: 10.1128/JCM.36.4.897-901.1998. View

5.
Tsakris A, Vatopoulos A, Tzouvelekis L, Legakis N . Diversity of resistance phenotypes and plasmid analysis in multi-resistant 0:12 Pseudomonas aeruginosa. Eur J Epidemiol. 1992; 8(6):865-70. DOI: 10.1007/BF00145334. View